New research reveals that patients who come off new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who end traditional diet and exercise programs.
Published data in a leading health publication points out that while overweight individuals often shed substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Individuals using these medications need to be aware of the potential of rapid rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
That rate of regain means a return to pre-treatment weight in about 18 months.
Analyzing Approaches
The research, which examined dozens of studies involving thousands of patients, compared the outcomes of the injectable medications with other pills.
Scientists note that people who lose weight through lifestyle changes alone generally see a slower weight regain—approximately 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Experts suggest the mode of action of the jabs accounts for the amplified rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to hunger is uncontrolled, making excessive eating a significant risk."
A Chronic Issue?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts contend that, considering the significant potential of relapse, the therapy should be considered long-term.
This perspective is supported by drug manufacturers, who say that the results "emphasize the persistent character of obesity," comparing it to managing diseases like hypertension.
User Testimonies
Users who have come off the medication report a sudden resurgence of appetite.
"I experienced a switch activating and you become starving," recalled one woman.
This difficulty is worsened if users have not adopted permanent lifestyle or habit changes during therapy.
Growing Adoption
Figures show that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Use is higher among females than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic cure and long-term success likely depends on combined behavioural management.
